Back to Main

CEO of Alexion Pharmaceuticals Inc. Leonard Bell Sold 140,000 Shares

By: GuruFocus
Posted: 8/19/2013 1:24:00 PM
Referenced Stocks: ALXN

Alexion Pharmaceuticals Inc. is a biopharmaceutical company focused on serving patients with severe and ultra-rare disorders through the innovation, development and commercialization of life-transforming therapeutic products. The company has a market cap of $20.53 billion; its shares were traded at around $105.00 with a P/E ratio of 59.52 and P/S ratio of 15.89. Alexion Pharmaceuticals Inc. had an annual average earnings growth of 70.6% over the past five years.

CEO of Alexion Pharmaceuticals Inc. ( ALXN ) Leonard Bell sold 140,000 shares on Aug. 16, 2013 at an average price of $106.08. The total transaction amount was $14,851,200.

Leonard Bell, currently the CEO of Alexion Pharmaceuticals Inc., was the primary founder of this company. Before founding Alexion Pharmaceuticals, Mr. Bell worked at Yale University as an assistant professor of medicine and pathology and a co-director of the program in vascular biology.

CEO Leonard Bell also sold 287,989 shares during May, July, and the beginning of August. CFO and EVP Vikas Sinha also sold 51,847 shares during July and August. Other officers and directors sold shares as well.



GuruFocus Guru Frank Sands kept his position in ALXN unchanged. He still owns 8,424,567 shares as of June 30, 2013. On the other hand, Andreas Halvorsen reduced his position in Alexion Pharmaceuticals Inc. by 41.4% and owns 5,544,949.

Alexion Pharmaceuticals Inc. reported its 2013 second quarter financial results with revenues of $274.7 million and net income of $36.3 million.

Read More:


About GuruFocus: GuruFocus.com tracks the stocks picks and portfolio holdings of the world's best investors. This value investing site offers stock screeners and valuation tools. And publishes daily articles tracking the latest moves of the world's best investors. GuruFocus also provides promising stock ideas in 3 monthly newsletters sent to Premium Members .